# Duke Street Bio

Source: https://onco.cc/companies/duke-street-bio/  
OnCo record `duke-street-bio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Duke Street Bio makes DSB2455, a tablet drug that blocks PARP1, a DNA repair enzyme some cancers rely on, while sparing a related enzyme linked to blood-count side effects. It is in an early trial for advanced cancers with DNA repair defects, including cancer that has spread to the brain.

## Summary

Duke Street Bio Ltd, at 2 Duke Street, London, develops small molecules against DNA damage repair deficiencies in cancer and immuno-oncology targets; it emerged from stealth in May 2022 discussing PARP1 and PARP7 inhibitor programmes. Its development candidate DSB2455 is a brain-penetrant PARP1 inhibitor that the company says is highly selective over PARP2, whose inhibition is linked to blood toxicity with first-generation PARP inhibitors. The European Medicines Agency approved a clinical trial in September 2024, the first patient was dosed in a phase 1 trial in December 2024, and in June 2025 the FDA granted Fast Track designation for patients with homologous recombination deficient brain metastases from triple-negative breast cancer. The registry lists breast, ovarian, metastatic castration-resistant prostate and pancreatic cancers and brain metastases with homologous recombination deficiency. Its first registered cancer trial, NCT06458712, was posted on ClinicalTrials.gov in June 2024.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Duke Street Bio Ltd
- HQ: London
- Type: biotech
- Website: https://dukestbio.com/

## Notes

- Founding year not stated on the company website.
- The registry contact domain dukesb.com did not serve a website; the company site is at dukestbio.com.
- No financing round was found on the company website; none is recorded.
- Company website and news page read on 29 October 2026; the individual releases were read only as summarised on the news page.

## Sources

- Official website: https://dukestbio.com/
- Company news, including the Fast Track designation and first patient dosed: https://dukestbio.com/news/
- ClinicalTrials.gov: phase 1 trial of DSB2455 in advanced cancers with homologous recombination deficiency (NCT06458712): https://clinicaltrials.gov/study/NCT06458712

## Connected records

- cancers: [Brain metastases (secondary brain tumours)](https://onco.cc/cancers/secondary-brain-tumours/), [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/), [Synthetic lethality approaches](https://onco.cc/technologies/synthetic-lethality-approaches/)
- targets: [PARP](https://onco.cc/targets/parp/)
- trials: [Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies](https://onco.cc/trials/nct06458712/)

---
JSON: https://onco.cc/api/v1/entities/duke-street-bio.json